EZH2 and non-small cell lung carcinoma: For instance, a meta-analysis by Fan et al. (2020), involving 2180 cases of non-small cell lung carcinoma (NSCLC), revealed that high EZH2 expression in lung adenocarcinoma indicated a poorer prognosis with shorter median survival time [20].